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In the years before direct revascularisation for drug-refrac-
tory angina pectoris, some indirect methods were explored
to improve myocardial ischaemia. Carotid nerve stimu-
lation activated by the patient when angina emerged and
Vineberg surgery [1] with implantation of the free end
of the mammary artery (started about 1963) are exam-
ples of desperate attempts to suppress untreatable symp-
toms. Both were abandoned because of non-proven effects
in contrast to direct revascularisation, which arrived around
1967. The favourable effects and safety of the current per-
cutaneous coronary intervention and bypass surgery permit
direct revascularisation in almost all categories of patients
with myocardial ischaemia. However, for some patients
direct revascularisation or redo procedures are not feasi-
ble because of the poor condition of the coronary arteries,
age or major comorbidity; the number of these patients is
gradually increasing. This observation initiates new exper-
imental, non-invasive methods to improve coronary circu-
lation and myocardial perfusion with the option of relief of
untreatable angina. These attempts vary from nerve stimu-
lation to gene therapy [2].
Acoustic pulse waves are used in an experimental at-
tempt to eradicate drug-refractory angina because it ini-
tiates angiogenesis in experimental conditions [3]. With
an amount of energy about 10 % of that usually applied
to crush kidney stones, several favourable bio-effects have
been documented. An increase of vascular endothelial
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growth factor and of capillary density resulting in a better
left ventricular ejection fraction, wall thickening fraction
and myocardial blood flow of the ‘treated’ area could be
documented. Several preliminary studies in patients with
severe angina pectoris without other therapeutic options
could show promising results in qualitative terms. How-
ever, as Slikkeveer and coworkers [4] stated, quantitative
observations of changes of myocardial blood flow in the
target ischaemic area after application of acoustic pulse
waves have not been published until now.
In their small pilot study of patients with severe angina
pectoris and major coronary disease, these authors could
not observe an obvious improvement of the blood flow four
weeks after the last application of acoustic pulse waves by
measuring myocardial blood flow with cardiac magnetic
resonance imaging (CMR) [5]. Nevertheless, despite an
unchanged frequency of angina attacks, some improvement
in the physical condition and less use of nitroglycerin were
noted. The authors concluded that this negative outcome re-
quires more scientific insight into the bio-effects of acoustic
pulse waves before further clinical exploration can be jus-
tified.
With full appreciation for the efforts of the investigators,
some elements of this clinical pilot study that might af-
fect the reported results should be pointed out. The course
of patient symptoms, timing and methods of measurement
of myocardial blood flow after acoustic pulse waves, and
‘collateral damage’ of tissue beyond the target zone are
questionable. The unchanged frequency of attacks con-
flicts with a better perceived physical condition according
to New York Heart Association class, and less daily use of
nitroglycerin, respectively. Despite use of a disease-specific
quality of life questionnaire, one can safely assume that the
small cohort of patients, as well as a placebo effect resulting
from frequent and intensive attention and care of the study
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patients, affect the documented changes of health percep-
tion and symptoms. Therefore this part of the outcome of
the pilot study can be classified as arbitrary.
The follow-up time after application of the acoustic pulse
waves needs to be questioned. At three months after the last
application, quality of life was again determined whereas
the time of the second CMR was not precisely presented,
presumably in conjunction with filling out the question-
naire, in total about 5 months after the last application. This
interval appears too short to permit a reliable quantifica-
tion of new angiogenesis and presumably other bio-effects.
In the past, at least 6 months of follow-up after Vineberg
surgery was required to determine any contribution of the
implanted artery to myocardial perfusion. A longer follow-
up and an additional CMT, e. g. after a further six months,
could have shown a different picture.
The acoustic pulse waves were applied towards previ-
ously mapped ischaemic zones. To catch the entire zone,
the application area was extended including ‘treatment of
healthy segments’ [4]. This approach can elicit negative
effects because the bio-effects on ‘normal’ human myocar-
dial tissue with a fixed dosage are uncertain. More im-
portantly, the so-called ischaemic zone in the end stage
of coronary heart disease is a conceptual area rather than
a well-described entity. Pathology of these hearts shows
unclear border zones intermingled with fibrosis, scar tissue
and surviving myocytes [6]. That mixture excludes a sharp
anatomical separation of the target zone and healthy neigh-
bours without ischaemia and complicates the direction and
penetration of the ‘beam’ of the acoustic pulse waves. One
can consider whether application of pulsed acoustic waves
in this specific patient group brought more harm as possi-
ble ‘collateral damage’ of tissue beyond the target area than
benefit.
CMR is well established for assessing myocardial
volumes and function, and for myocardial fibrosis and
(non)ischaemic heart diseases. In regions with reduced
perfusion, concentrations of Gadolinium are decreased,
resulting in lower signal intensity. Recently, different
techniques have been developed to improve quantification,
aiming to determine a reliable tissue function. None of
these techniques were employed in this study. The accu-
racy of the employed quantification technique is insufficient
to calculate absolute flow in these difficult areas [7].
We agree with the authors that our knowledge of the
bio-effects of pulsed acoustic wave shocks applied to spe-
cific myocardial targets is so limited that more knowledge
is strongly needed. Consequently one cannot explore this
‘treatment’ in new patients before we know more about
the precise individual dosages, the optimal timing and the
best method to measure positive and side effects of acous-
tic pulse waves. Until now, this indirect treatment has not
proven to constitute a beneficial and harmless “weapon”
against drug-refractory angina. Whether other treatment
indications in cardiology can profit from acoustic pulse
waves, also remains questionable.
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